Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Nura Bio

Private
#Amyotrophic lateral sclerosis (ALS)#Multiple sclerosis#Peripheral neuropathy

Clinical-stage neuroscience company developing SARM1 inhibitors for neurodegeneration including ALS and multiple sclerosis.

Company Info

Sector:Small Molecule Pharma
Headquarters:San Diego, California, USA
Founded:2018
Website:nurabio.com/
Funding Round:Series A
Total Funding:$73.8M (latest round, total undisclosed)

Funding & Investor Relations

Notable Investors

  • Undisclosed venture investors

Upcoming Milestones & Key Dates

2027 H1
Regulatory filing

IND filing for NB-100 in ALS

2026 H2
Financing event

Series B financing

Clinical Development Pipeline

NB-100

Target: SARM1 inhibitor
ALS
Preclinical
Phase 1
Phase 2
Phase 3
Approved

NB-200

Target: SARM1 inhibitor
Multiple sclerosis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

NB-300

Target: SARM1 inhibitor
Peripheral neuropathy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Shilpa Sambashivan, Ph.D.

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →